Circulating tumor DNA in ALK-positive anaplastic large cell lymphoma: a proof-of-concept study.

ABSTRACT: In this multicenter study, we were able to detect circulating tumor DNA (ctDNA) in 87.5% of patients with the rare disease ALK + ALCL. Moreover, by analyzing ctDNA from samples collected at disease progression, we were able to identify resistance mutations to ALK inhibitors. Furthermore, ctDNA proved to be a valuable and consistent tool for monitoring minimal residual disease.

SUBMITTER: Vasseur D 

PROVIDER: S-EPMC12116725 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature